Literature DB >> 17636327

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Elvira Montero1, Carmen Abreu, Paola Tonino.   

Abstract

PURPOSE: The vascular endothelial growth factor (VEGF) and p53 play important roles in the growth of tumor. However, the relationship between the expression of VEGF and p53 and tumor cell proliferation in human gastrointestinal cancer remains unknown. In the present study, therefore, we have examined the relationship between VEGF and p53 expression and tumor cell proliferation in gastrointestinal carcinoma (GITC), as well as the association between these biomarkers and clinicopathological factors.
METHODS: Surgical specimens from 30 patients with GITC were examined for VEGF, p53, and proliferating cell nuclear antigen (PCNA) expression by immunohistochemical staining.
RESULTS: We found a predominant VEGF expression of moderate intensity in 16(54.84%) of 30 GITC cases, while p53 expression was mainly high in 13(45.16%) of 30 GITC cases. PCNA expression was high in 20(64.52%) of 30 GITC cases. Tumor size, infiltration, vascular invasion, and gastritis were significantly correlated with VEGF, p53, and PCNA expression. There was a significant correlation between VEGF and p53 expression (P = 0.0001), VEGF and PCNA expression (P = 0.00004), and between p53 expression and PCNA expression (P = 0.0016). When the VEGF and p53 expression, and PCNA expression were considered together, both VEGF and p53 expression were not significantly associated with PCNA. A significant correlation between the PCNA expression and the mitotic index (P = 0.0016) was also found.
CONCLUSION: These results demonstrate that VEGF and p53 expression are significantly correlated as independent prognostic factors with tumor cell proliferation, and might be associated with relevant events involved in gastrointestinal tumor biology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636327     DOI: 10.1007/s00432-007-0270-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  56 in total

Review 1.  Regulation of p53 function.

Authors:  D B Woods; K H Vousden
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 2.  Clinical application of morphologic and immunocytochemical assessments of cell proliferation.

Authors:  M D Linden; F X Torres; J Kubus; R J Zarbo
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

3.  Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.

Authors:  Eliseo Mattioli; Paraskevi Vogiatzi; Ang Sun; Giovanni Abbadessa; Giulia Angeloni; Domenico D'Ugo; Daniela Trani; John P Gaughan; Fabio Maria Vecchio; Gabriele Cevenini; Roberto Persiani; Antonio Giordano; Pier Paolo Claudio
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

4.  Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma.

Authors:  K Maeda; S M Kang; N Onoda; M Ogawa; Y Kato; T Sawada; K H Chung
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

Review 5.  Tumor growth patterns and biological characteristics of early gastric carcinoma.

Authors:  Y Maehara; Y Kakeji; S Oda; H Baba; K Sugimachi
Journal:  Oncology       Date:  2001       Impact factor: 2.935

6.  Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.

Authors:  Stefano La Rosa; Silvia Uccella; Giovanna Finzi; Luca Albarello; Fausto Sessa; Carlo Capella
Journal:  Hum Pathol       Date:  2003-01       Impact factor: 3.466

7.  Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract.

Authors:  Mutsuo Furihata; Atsushi Kurabayashl; Manabu Matsumoto; Hiroshi Sonobe; Yuji Ohtsuki; Naotami Terao; Morimasa Kuwahara; Taro Shuin
Journal:  J Pathol       Date:  2002-05       Impact factor: 7.996

8.  Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer.

Authors:  K Maeda; S M Kang; N Onoda; M Ogawa; T Sawada; B Nakata; Y Kato; Y S Chung; M Sowa
Journal:  Oncology       Date:  1998 Nov-Dec       Impact factor: 2.935

9.  Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus.

Authors:  A R Rosa; C C Schirmer; R R Gurski; L Meurer; M I Edelweiss; C D Kruel
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

10.  Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.

Authors:  Y Maehara; M Tomoda; S Hasuda; A Kabashima; E Tokunaga; Y Kakeji; K Sugimachi
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  8 in total

Review 1.  Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.

Authors:  Shuyang Yao; Funda Meric-Bernstam; David Hong; Filip Janku; Aung Naing; Sarina Anne Piha-Paul; Apostolia Maria Tsimberidou; Daniel Karp; Vivek Subbiah; Timothy Anthony Yap; Jordi Rodon Ahnert; Shubham Pant; Ecaterina E Ileana Dumbrava; Chetna Wathoo; Erick Campbell; Lihou Yu; Yuko Yamamura; Siqing Fu
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

2.  HSPA12B: a novel facilitator of lung tumor growth.

Authors:  He Ma; Ting Lu; Xiaojin Zhang; Chuanfu Li; Jingwei Xiong; Lei Huang; Ping Liu; Yuehua Li; Li Liu; Zhengnian Ding
Journal:  Oncotarget       Date:  2015-04-30

3.  Pro-apoptotic and migration-suppressing potential of EGCG, and the involvement of AMPK in the p53-mediated modulation of VEGF and MMP-9 expression.

Authors:  Song Yi Park; Chang Hee Jung; Bokyung Song; Ock Jin Park; Young-Min Kim
Journal:  Oncol Lett       Date:  2013-08-19       Impact factor: 2.967

4.  A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.

Authors:  Fujun Dai; Yihua Chen; Yajuan Song; Li Huang; Dong Zhai; Yanmin Dong; Li Lai; Tao Zhang; Dali Li; Xiufeng Pang; Mingyao Liu; Zhengfang Yi
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

5.  Microvessel Density Is Associated with VEGF and α-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas.

Authors:  Paola Tonino; Carmen Abreu
Journal:  Cancers (Basel)       Date:  2011-08-31       Impact factor: 6.639

6.  Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.

Authors:  Ming-Mo Hou; Zhijie Wang; Filip Janku; Sarina Piha-Paul; Aung Naing; David Hong; Shannon Westin; Robert L Coleman; Anil K Sood; Apostolia M Tsimberidou; Vivek Subbiah; Jennifer Wheler; Ralph Zinner; Karen Lu; Funda Meric-Bernstam; Siqing Fu
Journal:  Oncotarget       Date:  2016-06-07

7.  Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.

Authors:  Yudong Wang; Filip Janku; Sarina Piha-Paul; Kenneth Hess; Russell Broaddus; Lidong Liu; Naiyi Shi; Michael Overman; Scott Kopetz; Vivek Subbiah; Aung Naing; David Hong; Apostolia M Tsimberidou; Daniel Karp; James Yao; Siqing Fu
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

Review 8.  Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.

Authors:  Hui Li; Jinglin Zhang; Joanna Hung Man Tong; Anthony Wing Hung Chan; Jun Yu; Wei Kang; Ka Fai To
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.